BPC-157: Preclinical Research Overview

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide derived from a partial sequence of a protein found in human gastric juice. Its published sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), with molecular formula C62H98N16O22 and molecular weight approximately 1419.5 g/mol.

It is often described in supplier marketing in terms far beyond what the literature supports. The accurate description is narrower: BPC-157 is a peptide with an extensive rodent literature and essentially no human clinical evidence.

Published preclinical work proposes several mechanisms rather than one established pathway. These include modulation of the nitric oxide system, VEGFR2-mediated angiogenic signaling, FAK-paxillin signaling in cell migration and adhesion, and interaction with growth hormone receptor pathways in tissue repair models.

All of these are hypotheses supported by animal and cell-level observations. None constitute a confirmed mechanism of action in humans.

The identified literature consists of rodent studies examining gastrointestinal injury, vascular occlusion, ischemia-reperfusion injury, tendon and ligament injury models, and severe electrolyte disturbance. Reported findings include accelerated healing responses, reduced ischemia-reperfusion damage, and recovery from vessel occlusion, attributed by the authors to nitric-oxide-pathway and angiogenic modulation.

Two structural caveats deserve emphasis. First, the evidence is exclusively preclinical — there are no verified human clinical trials or regulatory filings. Second, a large share of the primary literature originates from a single research group (Sikiric and colleagues in Zagreb), which limits independent replication. Recent review articles, including a 2026 review of tendon, ligament, and muscle injury therapy perspectives, restate this literature but do not add human trial data.

BPC-157 has no FDA-approved indication and is not established as safe or effective in humans. It is included on the World Anti-Doping Agency prohibited list, which is relevant context for any research program touching sports science.

Supplied lyophilized in a sealed vial. Keep dry and sealed, equilibrate before opening, reconstitute with an appropriate solvent for the assay, aliquot to avoid repeated freeze-thaw cycles, and keep reconstituted solutions cold and shielded from light. Record the lot number so results remain traceable to the certificate for that material.

This monograph summarizes published scientific literature for educational and reference purposes only. It is not medical, veterinary, clinical, or dosing guidance, and nothing here should be read as a claim that this compound is safe, effective, or approved for use in humans or animals.

Material supplied by North Summit Labs is intended strictly for in-vitro laboratory research by qualified professionals. It is not a drug, supplement, food, cosmetic, or medical device, and it is not for human or animal consumption. Investigators are responsible for complying with their own institutional oversight, biosafety, and legal requirements.